FdaApplication
NDA 021131
Identifiers
- fda_app_no: NDA021131
Properties
| Property | Value |
|---|---|
| applicant_name | PFIZER INC |
| application_type | NDA |
| approval_date | 2000-04-18 |
Revenue by product
ZYVOX
| Period | Revenue |
|---|---|
| Q3 2021 | $41.0M |
| Q2 2021 | $48.0M |
| Q1 2021 | $55.0M |
| Q3 2020 | $51.0M |
| Q2 2020 | $55.0M |
| Q1 2020 | $70.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients.
Products (3)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| ZYVOX | LINEZOLID | 400MG/200ML (2MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLUTION;INTRAVENOUS |
| ZYVOX | LINEZOLID | 600MG/300ML (2MG/ML) | SOLUTION;INTRAVENOUS |
| ZYVOX | LINEZOLID | 200MG/100ML (2MG/ML) | SOLUTION;INTRAVENOUS |
3 products